导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.40% | 2307/4773 |
| 近一周 | -2.55% | 4032/5465 |
| 近一月 | -7.03% | 4416/5421 |
| 近一季 | -13.92% | 4211/5231 |
| 近半年 | -2.03% | 1993/4920 |
| 近一年 | 2.85% | 2181/4394 |
| 近两年 | 63.66% | 1149/2954 |
| 近三年 | 33.94% | 946/2253 |
| 成立以来 | 114.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.75% 2462/4961 |
22.09% 1138/5312 |
- - |
- - |
| 2025 | 27.23% 1572/4813 |
-0.74% 2385/3635 |
-0.69% 3001/4076 |
31.74% 1109/4524 |
-2.03% 3074/4813 |
| 2024 | 13.64% 1124/3463 |
0.43% 978/2808 |
-3.38% 1361/3014 |
21.02% 635/3129 |
-3.23% 2298/3463 |
| 2023 | -15.75% 1657/2656 |
4.56% 919/2280 |
-6.25% 1607/2385 |
-7.51% 1583/2515 |
-7.07% 2040/2655 |
| 2022 | -24.67% 1242/2207 |
-18.72% 1381/1919 |
9.18% 294/2016 |
-16.58% 1470/2113 |
1.76% 1156/2208 |
| 2021 | 0.92% 700/1822 |
-4.54% 871/1255 |
11.09% 402/1330 |
-7.74% 1079/1466 |
3.15% 467/1822 |
| 2020 | 51.87% 156/1250 |
-5.91% 445/1028 |
22.27% 215/1067 |
11.23% 464/1164 |
18.68% 87/1184 |
| 2019 | 56.34% 66/1092 |
38.12% 68/754 |
-3.02% 371/804 |
4.85% 178/850 |
11.31% 65/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 方正富邦深证100ETF VS. 长安沪深300非周期A(740101) |